Category: FDA Approval and Clinical Trials

New FDA Approval Offers Hope for Classic CAH Patients
FDA Approval and Clinical Trials

New FDA Approval Offers Hope for Classic CAH Patients

A New Hope for Patients with Classic CAH For those living with classic congenital adrenal hyperplasia (CAH), managing everyday life often feels like an uphill battle. But now, there’s promising news. On 13th December 2024, Crenessity (crinecerfont) was officially approved by the U.S. Food and Drug Administration.This new medication is used alongside steroids (glucocorticoids). It […]

  • 30/12/2024
Osimertinib as a First-Line Therapy: Key Approvals and Benefits for Lung Cancer Patients
Cancer Medicine

Osimertinib as a First-Line Therapy: Key Approvals and Benefits for Lung Cancer Patients

Osimertinib, a revolutionary drug in treating EGFR-mutant non-small cell lung cancer (NSCLC), is making waves in oncology. Osimertinib, also known as Tagrisso. Developed initially as a second-line treatment for patients with resistant forms of lung cancer, Osimertinib has gained importance as a first-line therapy in recent years. With its ability to target specific mutations and prolong […]

  • 30/08/2024